Credicorp Ltd. Faces Regulatory Scrutiny Over Fatalities Linked to Defective Saline Solution at SANNA Clinics

Reuters
05-20
<a href="https://laohu8.com/S/BAP">Credicorp Ltd</a>. Faces Regulatory Scrutiny Over Fatalities Linked to Defective Saline Solution at SANNA Clinics

Credicorp Ltd., a company with securities registered in the Public Registry of the Securities Market, has been mandated to disclose material information regarding serious incidents at its affiliated clinics, Clínica SANNA San Borja and Clínica SANNA Trujillo. These incidents involve the administration of defective saline solution to patients, resulting in fatalities. As the ultimate controller of these clinics within the Credicorp Economic Group, Credicorp is required to disclose this information truthfully, sufficiently, and timely, as per the mandatory legal provisions and regulations. The company has been given a two-business-day deadline to comply with this requirement and must ensure ongoing transparency regarding any significant developments related to these events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Credicorp Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-019791), on May 19, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10